Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 11

Results For "2022"

1412 News Found

President Murmu addresses Golden Jubilee Celebrations of NIMHANS
News | January 04, 2025

President Murmu addresses Golden Jubilee Celebrations of NIMHANS

Inaugurates new facilities to further NIMHANS’ mission of delivering cutting-edge care in mental health and neurosciences


President of India inaugurates KLE Cancer Hospital
News | January 04, 2025

President of India inaugurates KLE Cancer Hospital

The President said that there is a need to spread more and more awareness regarding the causes, diagnosis and treatment of cancer


Venus Remedies secures GMP certification for antibiotic carbapenem facility in Moldova
Drug Approval | January 01, 2025

Venus Remedies secures GMP certification for antibiotic carbapenem facility in Moldova

Expects to unlock further opportunities in the Moldovan market, contributing anticipated sales of $300,000 in 2025 and approximately $700,000–$800,000 in 2026


Immedica to acquire biopharmaceutical company Marinus Pharmaceuticals
News | December 31, 2024

Immedica to acquire biopharmaceutical company Marinus Pharmaceuticals

Immedica to commence a cash tender offer to acquire all issued and outstanding shares of Marinus for an enterprise value of approximately US$ 151 million


Reliance acquires Karkinos Healthcare for Rs. 375 Cr
Healthcare | December 29, 2024

Reliance acquires Karkinos Healthcare for Rs. 375 Cr

Karkinos is in the business of providing technology-driven, innovative solutions for the early detection, diagnosis, and management of cancer.


Thyrocare secures NABL accreditation for its Labs
News | December 27, 2024

Thyrocare secures NABL accreditation for its Labs

Thyrocare becomes first national diagnostic chain with 100% of its labs with NABL accreditation


Lynparza demonstrated clinically meaningful prolonged survival benefit in early breast cancer in OlympiA Phase 3 trial
Diagnostic Center | December 12, 2024

Lynparza demonstrated clinically meaningful prolonged survival benefit in early breast cancer in OlympiA Phase 3 trial

First and only PARP inhibitor to improve overall survival in early breast cancer


Torrent Pharma inks agreement with Boehringer Ingelheim to acquire 3 anti-diabetes brands
News | December 05, 2024

Torrent Pharma inks agreement with Boehringer Ingelheim to acquire 3 anti-diabetes brands

The acquisition further strengthens Torrent’s existing diabetes care portfolio and its presence in the Oral Anti Diabetic market


Pfizer appoints Chris Boshoff as Chief Scientific Officer and President, Research & Development
People | November 21, 2024

Pfizer appoints Chris Boshoff as Chief Scientific Officer and President, Research & Development

Roger Dansey to become Interim Chief Oncology Officer and Johanna Bendell to join Pfizer as Oncology Chief Development Officer